Dr. Noubar Afeyan, Flagship's Managing Partner and CEO, speaking on Investor Panel at BIO World Congress on Industrial Biotechnology & Bioprocessing
Dr. Noubar Afeyan, Flagship's Managing Partner and CEO, speaking on Investor Panel at BIO World Congress on Industrial Biotechnology & Bioprocessing
Click here to see announcement.
Michigan Growth Capital Symposium Unveils Flagship Ventures' Noubar Afeyan as Keynote Speaker
Michigan Growth Capital Symposium Unveils Flagship Ventures' Noubar Afeyan as Keynote Speaker
Society for Biological Engineering Announces Inaugural Winners of Wang Award
Society for Biological Engineering Announces Inaugural Winners of Wang Award
NEW YORK – The Society for Biological Engineering (SBE) of the American Institute of Chemical Engineers (AIChE) has announced the inaugural winners of the D. I. C. Wang Award for Excellence in Biochemical Engineering. The inaugural recipients of the award, established in appreciation of Professor Daniel I.C. Wang of the Massachusetts Institute of Technology (MIT), are Noubar Afeyan of Flagship Ventures and James Swartz of Stanford University.
Shire Adds new Technology Platform and Phase 2 Product Candidate to its Regenerative Medicine Business
Shire Adds new Technology Platform and Phase 2 Product Candidate to its Regenerative Medicine Business
Tangent Medical Submits FDA 510(k) for NovaCath™ Secure IV Catheter System
Tangent Medical Submits FDA 510(k) for NovaCath™ Secure IV Catheter System
First Targeted Nanomedicine to Enter Human Clinical Studies is a Paradigm Shift in Anti-tumor Efficacy and Safety in Cancer Patients
First Targeted Nanomedicine to Enter Human Clinical Studies is a Paradigm Shift in Anti-tumor Efficacy and Safety in Cancer Patients
BOSTON, MA—A team of scientists, engineers and physicians from Brigham and Women’s Hospital (BWH), Dana-Farber Cancer Institute (DFCI), Harvard Medical School (HMS), Massachusetts Institute of Technology (MIT), BIND Biosciences, Translational Genomics Research Institute (TGen), Wayne State University Karmanos Cancer Institute, and Weill Cornell Medical College have found promising effects of a first-in-class targeted cancer drug called BIND-014 in treating solid tumors.
Novel Prostate Nanomedicine Delivers High Drug Concentration Directlyand Safely to Tumors in Phase I Trials
Novel Prostate Nanomedicine Delivers High Drug Concentration Directlyand Safely to Tumors in Phase I Trials
Highly-Targeted Nanoparticles Act as “Trojan Horse” to Deliver Powerful Chemotherapy Agent Without Affecting Healthy Cells
Acceleron’s ACE-041 Combined with a VEGF Inhibitor Shows Potent Activity in Preclinical Model of VEGF-Resistant Renal Cell Carcinoma
Acceleron’s ACE-041 Combined with a VEGF Inhibitor Shows Potent Activity in Preclinical Model of VEGF-Resistant Renal Cell Carcinoma
-- Enhanced Anti-Tumor Activity Achieved via Combination of Two Distinct Anti-Angiogenic Drugs presented at the AACR Annual Meeting 2012 --
Bind Biosciences - Fierce's 5 Drug Delivery Companies to Watch
Bind Biosciences - Fierce's 5 Drug Delivery Companies to Watch
Company: Bind Biosciences
Headquarters: Cambridge, MA
Founded: 2006
Employees: 30
Core drug delivery technology: Bind's Accurins technology blends polymers with existing drugs to create an enhanced, controlled-release compound that hits a precise target with its payload. Bind's first drug, Bind-014, is a formulation of docetaxel, the active ingredient in Taxotere, a drug that treats breast, prostate, lung and other cancers.
